Biogen Inc. (NASDAQ:BIIB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have earned a consensus recommendation of “Moderate Buy” from the thirty-two analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $223.3571.

A number of analysts have commented on the company. Needham & Company LLC boosted their price objective on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Rothschild & Co Redburn lifted their target price on Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Morgan Stanley upped their price target on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a report on Thursday. Wall Street Zen cut Biogen from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Sanford C. Bernstein cut their price objective on shares of Biogen from $201.00 to $200.00 in a report on Thursday, April 30th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Vanguard Group Inc. increased its stake in Biogen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after buying an additional 157,857 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Biogen by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after acquiring an additional 130,618 shares during the last quarter. Norges Bank bought a new stake in Biogen during the fourth quarter worth $464,408,000. Invesco Ltd. boosted its position in Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after purchasing an additional 98,001 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Biogen by 3.3% during the 4th quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock valued at $409,180,000 after purchasing an additional 73,478 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

Biogen Stock Performance

Shares of BIIB stock opened at $202.95 on Monday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a fifty day simple moving average of $201.23 and a two-hundred day simple moving average of $190.64. Biogen has a 12 month low of $124.56 and a 12 month high of $219.72. The firm has a market capitalization of $29.99 billion, a PE ratio of 35.92, a price-to-earnings-growth ratio of 6.20 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the previous year, the firm posted $5.47 earnings per share. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Analysts forecast that Biogen will post 12.65 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.